.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 6,750,237

« Back to Dashboard

Claims for Patent: 6,750,237

Title: Pharmaceutical formulations containing zolmitriptan
Abstract:A pharmaceutical formulation of the 5HT1-agonist, zolmitriptan, for use in intranasal administration. The formulation is useful in treating migraine and related disorders.
Inventor(s): Dearn; Alan Roy (Ware, GB), Williamson; Sarah Louise (Ware, GB), Summers; Simon John (Ware, GB), Coomber; Trevor John (Ware, GB)
Assignee: AstraZeneca AB (London, GB)
Application Number:10/129,773
Patent Claims: 1. A pharmaceutical formulation suitable for intranasal administration which comprises zolmitriptan and a pharmaceutically acceptable carrier wherein the pH of the formulation is in the range 4.5 to 5.5.

2. A pharmaceutical formulation according to claim 1 wherein the pH of the formulation is 5.

3. A pharmaceutical formulation according to claim 1 wherein the formulation is buffered.

4. A pharmaceutical formulation according to claim 2 wherein the formulation is buffered.

5. A pharmaceutical formulation according to claim 1 which is sterile.

6. A pharmaceutical formulation according to claim 2 which is sterile.

7. A pharmaceutical formulation according to claim 3 which is sterile.

8. A pharmaceutical formulation according to claim 4 which is sterile.

9. A pharmaceutical formulation suitable for intranasal administration which comprises zolmitriptan and a pharmaceutically acceptable carrier wherein the pH of the formulation is less than 7.0, wherein the formulation is buffered by a mixture of citric acid and disodium phosphate.

10. A pharmaceutical formulation according to claim 9 which is sterile.

11. A pharmaceutical formulation suitable for intranasal administration which comprises zolmitriptan and a pharmaceutically acceptable carrier wherein the pH of the formulation is in the range 4.5 to 5.5, wherein the formulation is buffered by a mixture of citric acid and disodium phosphate.

12. A pharmaceutical formulation according to claim 11 which is sterile.

13. An intranasal administration device containing a pharmaceutical formulation as defined in any one of claims 1, 2, 9 or 11.

14. The intranasal administration device of claim 13, wherein the pharmaceutical formulation is packaged to protect the formulation from light.

15. An aqueous solution of zolmitriptan in a buffer at a pH in the range of 4.5 to 5.5.

16. The aqueous solution of claim 15, wherein the pH is 5.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc